148 related articles for article (PubMed ID: 37743328)
1. [Classification and Molecular Diagnosis of Benign Brain Tumors].
Yoshimoto K
No Shinkei Geka; 2023 Sep; 51(5):771-777. PubMed ID: 37743328
[TBL] [Abstract][Full Text] [Related]
2. A new amplicon-based gene panel for next generation sequencing characterization of meningiomas.
Mawrin C; Koch R; Waldt N; Sandalcioglu IE; Braunsdorf WEK; Warnke JP; Goehre F; Meisel HJ; Ewald C; Neyazi S; Schüller U; Kirches E
Brain Pathol; 2022 Mar; 32(2):e13046. PubMed ID: 35213080
[TBL] [Abstract][Full Text] [Related]
3. [Meningioma].
Sasaki H
No Shinkei Geka; 2023 Sep; 51(5):829-836. PubMed ID: 37743334
[TBL] [Abstract][Full Text] [Related]
4. Frequent AKT1E17K mutations in skull base meningiomas are associated with mTOR and ERK1/2 activation and reduced time to tumor recurrence.
Yesilöz Ü; Kirches E; Hartmann C; Scholz J; Kropf S; Sahm F; Nakamura M; Mawrin C
Neuro Oncol; 2017 Aug; 19(8):1088-1096. PubMed ID: 28482067
[TBL] [Abstract][Full Text] [Related]
5. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO.
Clark VE; Erson-Omay EZ; Serin A; Yin J; Cotney J; Ozduman K; Avşar T; Li J; Murray PB; Henegariu O; Yilmaz S; Günel JM; Carrión-Grant G; Yilmaz B; Grady C; Tanrikulu B; Bakircioğlu M; Kaymakçalan H; Caglayan AO; Sencar L; Ceyhun E; Atik AF; Bayri Y; Bai H; Kolb LE; Hebert RM; Omay SB; Mishra-Gorur K; Choi M; Overton JD; Holland EC; Mane S; State MW; Bilgüvar K; Baehring JM; Gutin PH; Piepmeier JM; Vortmeyer A; Brennan CW; Pamir MN; Kiliç T; Lifton RP; Noonan JP; Yasuno K; Günel M
Science; 2013 Mar; 339(6123):1077-80. PubMed ID: 23348505
[TBL] [Abstract][Full Text] [Related]
6. High-grade meningiomas: biology and implications.
Bi WL; Prabhu VC; Dunn IF
Neurosurg Focus; 2018 Apr; 44(4):E2. PubMed ID: 29606053
[TBL] [Abstract][Full Text] [Related]
7. Genomic Landscape of Meningiomas.
Wang JZ; Nassiri F; Mawrin C; Zadeh G
Adv Exp Med Biol; 2023; 1416():137-158. PubMed ID: 37432625
[TBL] [Abstract][Full Text] [Related]
8. Molecular alterations in meningioma: prognostic and therapeutic perspectives.
Birzu C; Peyre M; Sahm F
Curr Opin Oncol; 2020 Nov; 32(6):613-622. PubMed ID: 32890025
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma.
Abedalthagafi M; Bi WL; Aizer AA; Merrill PH; Brewster R; Agarwalla PK; Listewnik ML; Dias-Santagata D; Thorner AR; Van Hummelen P; Brastianos PK; Reardon DA; Wen PY; Al-Mefty O; Ramkissoon SH; Folkerth RD; Ligon KL; Ligon AH; Alexander BM; Dunn IF; Beroukhim R; Santagata S
Neuro Oncol; 2016 May; 18(5):649-55. PubMed ID: 26826201
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic and genomic profiling of chordoid meningioma: implications for clinical management.
Daoud EV; Zhu K; Mickey B; Mohamed H; Wen M; Delorenzo M; Tran I; Serrano J; Hatanpaa KJ; Raisanen JM; Snuderl M; Cai C
Acta Neuropathol Commun; 2022 Apr; 10(1):56. PubMed ID: 35440040
[TBL] [Abstract][Full Text] [Related]
11. Association of Genetic Predisposition With Solitary Schwannoma or Meningioma in Children and Young Adults.
Pathmanaban ON; Sadler KV; Kamaly-Asl ID; King AT; Rutherford SA; Hammerbeck-Ward C; McCabe MG; Kilday JP; Beetz C; Poplawski NK; Evans DG; Smith MJ
JAMA Neurol; 2017 Sep; 74(9):1123-1129. PubMed ID: 28759666
[TBL] [Abstract][Full Text] [Related]
12. Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations.
Reuss DE; Piro RM; Jones DT; Simon M; Ketter R; Kool M; Becker A; Sahm F; Pusch S; Meyer J; Hagenlocher C; Schweizer L; Capper D; Kickingereder P; Mucha J; Koelsche C; Jäger N; Santarius T; Tarpey PS; Stephens PJ; Andrew Futreal P; Wellenreuther R; Kraus J; Lenartz D; Herold-Mende C; Hartmann C; Mawrin C; Giese N; Eils R; Collins VP; König R; Wiestler OD; Pfister SM; von Deimling A
Acta Neuropathol; 2013 Mar; 125(3):351-8. PubMed ID: 23404370
[TBL] [Abstract][Full Text] [Related]
13. Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic.
Williams EA; Santagata S; Wakimoto H; Shankar GM; Barker FG; Sharaf R; Reddy A; Spear P; Alexander BM; Ross JS; Brastianos PK; Cahill DP; Ramkissoon SH; Juratli TA
Acta Neuropathol Commun; 2020 Oct; 8(1):171. PubMed ID: 33087175
[TBL] [Abstract][Full Text] [Related]
14. Genetic landscape of meningioma.
Yuzawa S; Nishihara H; Tanaka S
Brain Tumor Pathol; 2016 Oct; 33(4):237-247. PubMed ID: 27624470
[TBL] [Abstract][Full Text] [Related]
15. Biology and clinical management challenges in meningioma.
Mawrin C; Chung C; Preusser M
Am Soc Clin Oncol Educ Book; 2015; ():e106-15. PubMed ID: 25993161
[TBL] [Abstract][Full Text] [Related]
16. Meningioma genomics: a therapeutic challenge for clinicians.
Moussalem C; Massaad E; Minassian GB; Ftouni L; Bsat S; Houshiemy MNE; Alomari S; Sarieddine R; Kobeissy F; Omeis I
J Integr Neurosci; 2021 Jun; 20(2):463-469. PubMed ID: 34258948
[TBL] [Abstract][Full Text] [Related]
17. Slug, twist, and E-cadherin as immunohistochemical biomarkers in meningeal tumors.
Nagaishi M; Nobusawa S; Tanaka Y; Ikota H; Yokoo H; Nakazato Y
PLoS One; 2012; 7(9):e46053. PubMed ID: 23029385
[TBL] [Abstract][Full Text] [Related]
18. Frequent NF2 gene transcript mutations in sporadic meningiomas and vestibular schwannomas.
Lekanne Deprez RH; Bianchi AB; Groen NA; Seizinger BR; Hagemeijer A; van Drunen E; Bootsma D; Koper JW; Avezaat CJ; Kley N
Am J Hum Genet; 1994 Jun; 54(6):1022-9. PubMed ID: 7911002
[TBL] [Abstract][Full Text] [Related]
19. Molecular genetics of meningiomas: Building the roadmap towards personalized therapy.
Peyre M; Kalamarides M
Neurochirurgie; 2018 Mar; 64(1):22-28. PubMed ID: 25245924
[TBL] [Abstract][Full Text] [Related]
20. Genetic/molecular alterations of meningiomas and the signaling pathways targeted.
Domingues P; González-Tablas M; Otero Á; Pascual D; Ruiz L; Miranda D; Sousa P; Gonçalves JM; Lopes MC; Orfao A; Tabernero MD
Oncotarget; 2015 May; 6(13):10671-88. PubMed ID: 25965831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
